

Nuclera announces installment of eProtein Discovery System at leading universities in Taiwan

08 January 2026 | News

Installations at National Taiwan University and National Cheng Kung University expand Nuclera's global footprint with first commercial sales in Asia



UK-headquartered Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, has completed the first installations of eProtein Discovery in Asia, with systems now operational at the Department of Pharmacy and the Department of Chemistry at the National Taiwan University (NTU) College of Medicine and the Center for Bioscience and Biotechnology and Department of Chemical Engineering at the National Cheng Kung University (NCKU). These installations represent Nuclera's first commercial sales in Asia, marking a major milestone in the Company's global expansion strategy.

Following the installation of eProtein Discovery at leading academic institutes across the UK and Europe, the expansion into Taiwan further underscores the Company's accelerating global adoption and its growing role in enabling next-generation protein research worldwide.

The eProtein Discovery Systems were purchased by Show Chung Ho, President of YFY Academy and Founder of E Ink Holdings, and donated to support the capabilities of NTU and NCKU to facilitate continued research in protein drug development. The two universities will form a collaborative platform focused on protein drug discovery, ensuring Taiwan remains aligned with international progress in this rapidly advancing field.

Combining unique cell-free expression systems, novel digital microfluidics, and robust screening data, eProtein Discovery provides clear guidance on which protein has the best chance of success early on, thereby reducing the time, cost, and uncertainty traditionally associated with pro